meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all population
5
mNSCLC - L1 - EGFR mutant
mNSCLC - L1 - PDL1 negative
1
mNSCLC - L1 - PDL1 positive
14
mNSCLC - L1 - TMB>10Mb
1
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population
3
non squamous - mNSCLC - L1 - PDL1 positive
non squamous - mNSCLC - L1 - Wild Type (WT)
6
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population
4
squamous - mNSCLC - L1 - PDL1 positive
squamous - mNSCLC - L1 - Wild Type (WT)
immune chekpoint inhibitors
anti-PD-(L)1
cemiplimab
durvalumab based treatment
durvalumab alone
sintilimab based treatment
sintillimab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
All patients
PDL1 (TC0 and IC0 : <1% of TC and IC)
PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC)
PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC )
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
AE leading to treatment discontinuation (grade 3-4)
STRAE (any grade)
STRAE (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
Adrenal insufficiency TRAE (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Nephritis TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Alopecia AE (grade 3-4)
Anaemia AE (grade 3-4)
Asthenia AE (grade 3-4)
Back pain AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Fatigue AE (grade 3-4)
Nausea AE (grade 3-4)
Neutropenia AE (grade 3-4)
Pruritus AE (grade 3-4)
Pyrexia AE (grade 3-4)
Rash AE (grade 3-4)
Thrombocytopenia AE (grade 3-4)
Vomiting AE (grade 3-4)
Weight decreased AE (grade 3-4)
deaths (OS)
mNSCLC - L1 - all population
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all population
versus Standard of Care (SoC)
durvalumab plus tremelimumab vs. Standard of Care (SoC)
1
certainty unassessable
-6%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open